Sign In
Buy JNJ
$231.29
+2.90 (+1.27%)
At Close: Jun 22, 2026
Bayer files lawsuit against Johnson & Johnson, Janssen Biotech
10:43am, Monday, 23'rd Feb 2026
German pharmaceutical company Bayer said on Monday that it had filed a lawsuit in a New York court against Johnson & Johnson and Janssen Biotech Inc related to its Nubeqa prostate cancer drug.
Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA
10:28am, Monday, 23'rd Feb 2026
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that it has filed suit against Johnson & Johnson (J&J) and Janssen Biotech, Inc. in the United States District Court for the Southern District of
Johnson & Johnson vs. AbbVie: A Growth Showdown Amid Patent Cliffs
09:16am, Monday, 23'rd Feb 2026
JNJ's diversified model, $32B R&D push and 48% stock surge in a year raise the stakes in its battle with ABBV for healthcare dominance.
Johnson & Johnson: This Dividend King Could Anchor a Millionaire Retirement Portfolio
01:02pm, Sunday, 22'nd Feb 2026
Johnson & Johnson is a core player in global healthcare. A diverse portfolio, fortress-like balance sheet, and industry tailwinds cement a growing dividend.
The Only Healthcare Stock I'd Buy and Never Sell Might Be Johnson & Johnson
07:45am, Sunday, 22'nd Feb 2026
Johnson & Johnson is a Dividend King. Its size and breadth have allowed it to flourish despite the many changes in the healthcare space over the years.
AMJ Financial Wealth Management Buys 5,496 Shares of Johnson & Johnson $JNJ
03:32am, Sunday, 22'nd Feb 2026
AMJ Financial Wealth Management boosted its stake in Johnson and Johnson (NYSE: JNJ) by 642.1% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and
TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years
08:00am, Saturday, 21'st Feb 2026
More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term extension study, showing lasting disease con
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Has $13.61 Million Stock Holdings in Johnson & Johnson $JNJ
04:42am, Saturday, 21'st Feb 2026
Empirical Financial Services LLC d.b.a. Empirical Wealth Management grew its stake in shares of Johnson and Johnson (NYSE: JNJ) by 11.4% during the third quarter, according to the company in its most
Johnson & Johnson $JNJ Holdings Lifted by ANTIPODES PARTNERS Ltd
04:07am, Saturday, 21'st Feb 2026
ANTIPODES PARTNERS Ltd boosted its holdings in shares of Johnson and Johnson (NYSE: JNJ) by 2.6% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange
Why Is Johnson & Johnson (JNJ) Up 13% Since Last Earnings Report?
12:30pm, Friday, 20'th Feb 2026
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
American Express, Deere Drop Board Diversity Criteria as 78% Disclosure Rate Falls
07:47am, Friday, 20'th Feb 2026
American Express (AXP), Deere (DE) and Johnson and Johnson (JNJ) have removed diversity language from their board selection frameworks following engagement from t
Vanessa Broadhurst Sells 6,197 Shares of Johnson & Johnson (NYSE:JNJ) Stock
06:50am, Friday, 20'th Feb 2026
Johnson and Johnson (NYSE: JNJ - Get Free Report) EVP Vanessa Broadhurst sold 6,197 shares of the business's stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price
Fiera Capital Corp Reduces Stake in Johnson & Johnson $JNJ
06:10am, Friday, 20'th Feb 2026
Fiera Capital Corp lessened its stake in shares of Johnson and Johnson (NYSE: JNJ) by 4.1% during the undefined quarter, according to the company in its most recent filing with the Securities and Exch
Timothy Schmid Sells 22,623 Shares of Johnson & Johnson (NYSE:JNJ) Stock
04:57am, Friday, 20'th Feb 2026
Johnson and Johnson (NYSE: JNJ - Get Free Report) EVP Timothy Schmid sold 22,623 shares of the firm's stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an avera
Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)
05:30pm, Thursday, 19'th Feb 2026
Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)
